More than 11 million hits and floats Haizheng Pharmaceutical's withdrawal of a generic drug listing application

On the 16th, Hisun Pharmaceutical announced that its wholly-owned subsidiary, Hanhui Pharmaceutical, has received the "Drug Registration Application Termination Notice" from the State Food and Drug Administration regarding Hanhui Pharmaceutical's voluntary application for withdrawal of the drug registration application for irbesartan hydrochlorothiazide tablets, and agreed to withdraw it Registration application, termination of registration procedures.

On November 7, 2017, Hanhui Pharmaceutical submitted an application for the registration of irbesartan hydrochlorothiazide tablets to Zhejiang Food and Drug Administration according to category 4 of chemical drug registration classification and was accepted.

Irbesartan hydrochlorothiazide tablets are suitable for the treatment of essential hypertension.

Public data shows that the global sales of irbesartan hydrochlorothiazide tablets in 2019 were US$467,665,300, of which China sales were US$40,673,700; the global sales in 2020 were US$408,817,900, of which China sales were US$85,254,500.

Up to now, Hanhui Pharmaceutical has invested approximately RMB 11,596,600 in the product research and development project.